Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer
Condition: Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer
MeSH terms: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung
Intervention: OSI-774: erlotinib, TarcevaTM
Intervention description: 150 mg, 100 mg and 25 mg tablets
Intervention MeSH terms: Erlotinib Hydrochloride
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 81.0
Sex: All
Healthy volunteers: No
Keywords: non small cell lung cancer

Summary:

      The primary objective of this study is to determine the major objective response rate of
      OSI-774 in participants with unresectable or metastatic bronchioloalveolar cell variant of
      non-small cell lung cancer.

      This study is a Phase II study. The first study of OSI-774 was done to evaluate what dose
      should be given to patients with cancer has been completed. The purpose of this research
      study is to see whether this experimental treatment, called OSI-774, can cause a type of
      non-small cell lung cancer to stop growing or shrink. This study is sponsored by a company
      called Genentech, and is being done at Memorial Hospital, as well as other cancer centers
      around the country interested in developing new drugs for the treatment of this type of
      cancer.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Either bronchioloalveolar cell carcinoma or a variant thereof after review

          -  Clinical stage IIIB (malignant pleural or pericardial effusion) or IV or
             recurrent/medically inoperable disease

          -  Measurable or evaluable indicator lesions

          -  No prior or one chemotherapy regimen for NSCLC

          -  Three weeks since last chemotherapy, and three weeks since prior radiation therapy to
             a major bone-marrow containing area

          -  Karnofsky performance status > or = to 80% OR ECOG performance status ≤ or = to 1

          -  Life expectancy > or = to 8 weeks

          -  Adequate hematologic, renal and/or hepatic function: WBC > or = to 3,000/ul,
             hemoglobin > or = to 9.0 g/dl, platelet count > or = to 100,000/ul, total bilirubin <
             or = to 1.0 mg/dl, AST < than or = to 2.5 X UNL, creatinine < or = to 1.5 mg/dl or
             Clcr > or = to 55ml/min.

          -  Effective contraception

        Exclusion Criteria:

          -  Prior exposure to OSI-774 or other treatments targeting the HER family axis
             (e.g.-trastuzumab, ZD1839, C225, etc.)

          -  Two or more prior chemotherapy regimens

          -  Concurrent active cancer

          -  Uncontrolled central nervous system metastases (i.e. any known CNS lesion which is
             radiographically unstable, symptomatic and/or requiring escalating doses of
             corticosteroids)

          -  Pregnant or lactating women

          -  Malignancies within the past 5 years except for adequately treated carcinoma of the
             cervix or basal or squamous cell carcinomas of the skin

          -  Prior systemic cytotoxic chemotherapy for other malignant disease

          -  Significant medical history or unstable medical condition (unstable systemic disease:
             congestive heart failure, recent MI, unstable angina, active infection, uncontrolled
             hypertension).